NCT03260322: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects With Advanced Solid Tumors

NCT03260322
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic unstable central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03260322

Comments are closed.

Up ↑